Royalty Pharma to Present at Upcoming Investor Conferences
September 05, 2023 08:25 ET
|
Royalty Pharma plc
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: ...
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)
August 24, 2023 06:30 ET
|
Royalty Pharma plc
Royalty Pharma to pay Ferring $300 million upfront and a potential $200 million milestone payment in exchange for royalties on the sales of Ferring’s intravesical gene therapy Adstiladrin®...
Royalty Pharma Reports Second Quarter 2023 Results
August 08, 2023 07:00 ET
|
Royalty Pharma plc
Net cash provided by operating activities (GAAP) of $608 million and Adjusted Cash Receipts(1) (non-GAAP) of $545 millionAnnounced transactions of up to $1.7 billion year-to-date, including $659...
Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023
July 18, 2023 16:15 ET
|
Royalty Pharma plc
NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023 before the U.S....
Royalty Pharma Declares Third Quarter 2023 Dividend
July 17, 2023 16:15 ET
|
Royalty Pharma plc
NEW YORK, July 17, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2023 of $0.20 per Class A...
Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023 08:15 ET
|
Royalty Pharma plc
NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 44th Annual Global Healthcare Conference on June...
Royalty Pharma Reports First Quarter 2023 Results
May 09, 2023 07:00 ET
|
Royalty Pharma plc
Net cash provided by operating activities (GAAP) of $1,034 million and Adjusted Cash Receipts(1) (non-GAAP) of $1,131 millionAnnounced transactions of up to $1.6 billion in Q1 2023, including $600...
Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference
May 03, 2023 16:15 ET
|
Royalty Pharma plc
NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10,...
Royalty Pharma Declares Second Quarter 2023 Dividend
April 17, 2023 08:15 ET
|
Royalty Pharma plc
NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2023 of $0.20 per Class A...
Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023
April 13, 2023 09:01 ET
|
Royalty Pharma plc
NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023 before the U.S....